Fuhrman Alan — SEC insider filings
SEC reporting owner CIK 1303521. 26 insider filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2021-05-21 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 9,500 shares, $151,954 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 40.
- Largest priced transaction: purchase of 9,500 shares @ $16.00 ($151,954) in Tyra Biosciences, Inc., filed 2024-11-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | Chief Financial Officer | 13 | 1 leg · 9,500 sh · $151,954 | — | 14 |
| SpringWorks Therapeutics, Inc. (SWTX) | Director | 6 | — | — | 15 |
| Esperion Therapeutics, Inc. (ESPR) | Director | 4 | — | — | 6 |
| Checkmate Pharmaceuticals, Inc. (CMPI) | Director | 3 | — | — | 5 |
Insider filings — Fuhrman Alan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 951 @ $9.13 | EDGAR |
| 2026-05-07 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 20,000 @ $0 · Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 1,376 @ $9.13 | EDGAR |
| 2025-09-17 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 701 @ $9.13 | EDGAR |
| 2025-08-07 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Disposition to issuer (D): 24,727 · Disposition to issuer (D): 29,983 (derivative) · Disposition to issuer (D): 7,464 (derivative) · Disposition to issuer (D): 15,318 (derivative) · Disposition to issuer (D): 13,774 (derivative) · Disposition to issuer (D): 12,216 (derivative) | EDGAR |
| 2025-05-15 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 10,060 @ $0 | EDGAR |
| 2025-03-18 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 1,238 @ $9.78 | EDGAR |
| 2024-11-01 | 4 | Tyra Biosciences, Inc. (TYRA) | Purchase (P): 9,500 @ $16.00 | EDGAR |
| 2024-09-17 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 954 @ $12.48 | EDGAR |
| 2024-08-16 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 23,000 @ $0 · Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 4,095 @ $0 · Grant/award (A): 12,216 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 932 @ $12.48 | EDGAR |
| 2023-09-19 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 1,463 @ $12.50 | EDGAR |
| 2023-08-01 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 62,685 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 5,150 @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 4,648 @ $0 · Grant/award (A): 13,774 (derivative) @ $0 | EDGAR |
| 2023-01-03 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 32,800 (derivative) @ $0 · Grant/award (A): 328,000 (derivative) @ $0 | EDGAR |
| 2022-05-31 | 4 | Checkmate Pharmaceuticals, Inc. (CMPI) | Disposition to issuer (D): 246,671 (derivative) · Disposition to issuer (D): 10,030 (derivative) · Disposition to issuer (D): 22,736 (derivative) | EDGAR |
| 2022-05-27 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 4,818 @ $0 · Grant/award (A): 15,318 (derivative) @ $0 | EDGAR |
| 2021-10-29 | 4 | Checkmate Pharmaceuticals, Inc. (CMPI) | Grant/award (A): 246,671 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Checkmate Pharmaceuticals, Inc. (CMPI) | Grant/award (A): 10,030 (derivative) @ $0 | EDGAR |
| 2021-05-28 | 4 | Esperion Therapeutics, Inc. (ESPR) | Grant/award (A): 12,376 @ $0 | EDGAR |
| 2021-05-21 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 1,106 @ $0 · Grant/award (A): 6,998 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-05-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1303521 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs